Martin Noble
Affiliations: | 2004- | University of Oxford, Oxford, United Kingdom |
Google:
"Martin Noble"Mean distance: 9.81
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Rowland RJ, Korolchuk S, Salamina M, et al. (2024) Cryo-EM structure of the CDK2-cyclin A-CDC25A complex. Nature Communications. 15: 6807 |
| Rowland RJ, Heath R, Maskell D, et al. (2023) Cryo-EM structure of SKP1-SKP2-CKS1 in complex with CDK2-cyclin A-p27KIP1. Scientific Reports. 13: 10718 |
| Miller DC, Reuillon T, Molyneux L, et al. (2022) Parallel Optimization of Potency and Pharmacokinetics Leading to the Discovery of a Pyrrole Carboxamide ERK5 Kinase Domain Inhibitor. Journal of Medicinal Chemistry |
| Al-Khawaldeh I, Al Yasiri MJ, Aldred GG, et al. (2021) An Alkynylpyrimidine-Based Covalent Inhibitor That Targets a Unique Cysteine in NF-κB-Inducing Kinase. Journal of Medicinal Chemistry |
| Lochhead PA, Tucker JA, Tatum NJ, et al. (2020) Paradoxical activation of the protein kinase-transcription factor ERK5 by ERK5 kinase inhibitors. Nature Communications. 11: 1383 |
| Wood DJ, Korolchuk S, Tatum NJ, et al. (2018) Differences in the Conformational Energy Landscape of CDK1 and CDK2 Suggest a Mechanism for Achieving Selective CDK Inhibition. Cell Chemical Biology |
| Fazal L, Ahn M, Bevan L, et al. (2018) Abstract 1652: Development of a potent class of small molecule inhibitors of the MDM2-p53 protein-protein interaction Cancer Research. 78: 1652-1652 |
| Martin MP, Endicott JA, Noble MEM. (2017) Structure-based discovery of cyclin-dependent protein kinase inhibitors. Essays in Biochemistry. 61: 439-452 |
| Hallett ST, Pastok MW, Morgan RML, et al. (2017) Differential Regulation of G1 CDK Complexes by the Hsp90-Cdc37 Chaperone System. Cell Reports. 21: 1386-1398 |
| Whittaker SR, Barlow C, Martin MP, et al. (2017) Molecular profiling and combinatorial activity of CCT068127: A potent CDK2 and CDK9 inhibitor. Molecular Oncology |